Pelvic Surgery: Time and Advisability of Operation in Certain Pathological Conditions

Por Johnson, Douglas B.
Publicado em 1924

Treatment of NRAS-Mutant Melanoma

Por Johnson, Douglas B., Puzanov, Igor
Publicado no Curr Treat Options Oncol (2015)

BRAF(V600E) mutant melanoma presenting with cardiac involvement

Por Johnson, Douglas B., Sosman, Jeffrey A.
Publicado em 2014

Immune Checkpoint Inhibitors in NSCLC

Por Johnson, Douglas B., Rioth, Matthew J., Horn, Leora
Publicado em 2014

Nivolumab in melanoma: latest evidence and clinical potential

Por Johnson, Douglas B., Peng, Chengwei, Sosman, Jeffrey A.
Publicado no Ther Adv Med Oncol (2015)

Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma

Por Johnson, Douglas B, Puzanov, Igor, Kelley, Mark C
Publicado no Immunotherapy (2015)

Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia

Por Johnson, Douglas B., Smalley, Keiran S. M., Sosman, Jeffrey A.
Publicado em 2014

Systems Immune Monitoring in Cancer Therapy

Por Greenplate, Allison R., Johnson, Douglas B., Ferrell, P. Brent, Irish, Jonathan Michael
Publicado no Eur J Cancer (2016)

Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling

Por Rioth, Matthew J, Thota, Ramya, Staggs, David B, Johnson, Douglas B, Warner, Jeremy L
Publicado no J Am Med Inform Assoc (2016)

Clinically relevant genes and regulatory pathways associated with NRAS(Q61) mutations in melanoma through an integrative genomics approach

Por Jiang, Wei, Jia, Peilin, Hutchinson, Katherine E., Johnson, Douglas B., Sosman, Jeffrey A., Zhao, Zhongming
Publicado no Oncotarget (2014)

Melanoma driver mutations and immune therapy

Por Johnson, Douglas B., Lovly, Christine M., Sullivan, Ryan J., Carvajal, Richard D., Sosman, Jeffrey A.
Publicado no Oncoimmunology (2016)

Responses to immune checkpoint inhibitors in nonagenarians

Por Johnpulle, Romany A. N., Conry, Robert M., Sosman, Jeffrey A., Puzanov, Igor, Johnson, Douglas B.
Publicado no Oncoimmunology (2016)

Adult Neuroblastoma Complicated by Increased Intracranial Pressure: A Case Report and Review of the Literature

Por Stevens, Patrick L., Johnson, Douglas B., Thompson, Mary Ann, Keedy, Vicki L., Frangoul, Haydar A., Snyder, Kristen M.
Publicado em 2014

Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab

Por Shreders, Amanda, Joseph, Richard, Peng, Chengwei, Ye, Fei, Zhao, Shilin, Puzanov, Igor, Sosman, Jeffrey A., Johnson, Douglas B.
Publicado no Cancer Immunol Res (2016)

Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma

Por Beckermann, Kathryn E., Jolly, Pradeep C., Kim, Ju Y., Bordeaux, Jennifer, Puzanov, Igor, Rathmell, W. Kimryn, Johnson, Douglas B.
Publicado no J Immunother Cancer (2017)

Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti–PD-1 Therapy

Por Greenplate, Allison R., Johnson, Douglas B., Roussel, Mikael, Savona, Michael R., Sosman, Jeffrey A., Puzanov, Igor, Ferrell, P. Brent, Irish, Jonathan M.
Publicado no Cancer Immunol Res (2016)

Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review

Por Johnson, Douglas B., Peng, Chengwei, Abramson, Richard G., Ye, Fei, Zhao, Shilin, Wolchok, Jedd D., Sosman, Jeffrey A., Carvajal, Richard D., Ariyan, Charlotte E.
Publicado no Oncologist (2015)

Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center

Por Johnson, Douglas B., Friedman, Debra L., Berry, Elizabeth, Decker, Ilka, Ye, Fei, Zhao, Shilin, Morgans, Alicia K., Puzanov, Igor, Sosman, Jeffrey A., Lovly, Christine M.
Publicado no Cancer Immunol Res (2015)

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

Por Kanz, Bridgette A., Pollack, Megan H., Johnpulle, Romany, Puzanov, Igor, Horn, Leora, Morgans, Alicia, Sosman, Jeffrey A., Rapisuwon, Suthee, Conry, R. Martin, Eroglu, Zeynep, Johnson, Douglas B.
Publicado no J Immunother Cancer (2016)

Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy

Por Johnson, Douglas B., Wallender, Erika K., Cohen, Daniel N., Likhari, Sunaina S., Zwerner, Jeffrey P., Powers, Jennifer G., Shinn, Lisa, Kelley, Mark C., Joseph, Richard W., Sosman, Jeffrey A.
Publicado em 2013